PathAI
Enterprise AI pathology platform for diagnostics and drug development.
PathAI is a solid choice for large labs and biopharma teams that need FDA-cleared AI built into a cloud platform. Its deep integration with drug development workflows and FDA-qualified algorithms like AIM-MASH give it a unique edge. However, its enterprise-only pricing and reliance on digitized slides make it a poor fit for smaller practices. If you're evaluating alternatives, compare with Paige AI for diagnostic focus, or consider Lunit for research-driven tools if budget is tighter.
Verified 8d ago · liveness 69/100 · cite: rightaichoice.com/tools/pathai
- Large pathology labs with digital slide infrastructure
- Biopharma companies needing AI-powered biomarker analysis for trials
- Academic medical centers with digital pathology workflows
- Organizations that require a comprehensive, regulated digital pathology platform
- Small labs without digitized slide scanning capabilities
- Teams looking for a low-cost, plug-and-play AI tool
- Organizations that prefer on-premise, non-cloud deployments
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip PathAI if you're a small lab without digitized slide scanning infrastructure, or if you need a low-cost, plug-and-play AI tool that can be purchased online without enterprise negotiation.
Custom enterprise pricing likely includes per-slide or per-case fees that can escalate with volume, so request a detailed quote before committing.
PathAI's contact-based pricing fits large pharma and central labs that can negotiate volume-based deals. It's likely costlier than alternatives like Paige or Lunit, which offer more transparent tiers, but the investment is justified by FDA-qualified algorithms and deep biopharma integration.
In short
PathAI — Enterprise AI pathology platform for diagnostics and drug development. Best for Large pathology labs with digital slide infrastructure, Biopharma companies needing AI-powered biomarker analysis for trials, Academic medical centers with digital pathology workflows. Contact Sales pricing.
Viability Score
How well maintained and how widely used is PathAI? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: September 2026
How we score →Key Features
- AISight cloud-native digital pathology platform
- FDA 510(k) cleared for primary diagnosis
- CE-IVDR marked platform
- AIM-PDL1 biomarker quantification
- AIM-HER biomarker quantification
- AIM-ER biomarker quantification
- TumorDetect automated tumor detection
- ArtifactDetect artifact detection
- PathAssistDerm dermatopathology AI
- METPredict for MET expression analysis
- AIM-MASH for MASH clinical trials
- AIM-HI UC for ulcerative colitis endpoints
- IBDExplore for IBD research
- IHCExplore for immunohistochemistry analysis
- Central pathology laboratory operations support
About PathAI
PathAI is an enterprise-grade AI pathology platform designed for biopharma companies and anatomic pathology laboratories. It combines a cloud-native digital pathology system, AISight®, with a suite of AI algorithms that support diagnostic accuracy and accelerate drug development. The platform handles case management, image management, and AI applications across multiple histopathology use cases. PathAI's AI algorithms target specific clinical and research needs: AIM-PDL1, AIM-HER, and AIM-ER for biomarker quantification; TumorDetect for automated tumor detection; ArtifactDetect for slide artifact detection; PathAssistDerm for dermatopathology; METPredict for MET expression; AIM-MASH for MASH clinical trials (FDA qualified); AIM-HI UC for ulcerative colitis histopathology endpoints; IBDExplore for inflammatory bowel disease research; and IHCExplore for immunohistochemistry analysis. The platform is FDA 510(k) cleared for primary diagnosis and CE-IVDR marked, which makes it suitable for regulated diagnostic workflows. It also powers a large central pathology laboratory operation, backed by a network of over 450 board-certified pathologists and 32.5 million+ annotations. PathAI reports use by 90% of the top 15 biopharma companies. PathAI is best suited for large labs and research organizations that already have digitized slide scanning infrastructure. Its enterprise focus means it is not a plug-and-play tool for small practices. Compared to alternatives like Paige, PathAI emphasizes biopharma partnerships and a fully integrated cloud platform, but buyers should weigh the cost and integration complexity before committing.
Behind the Verdict
PathAI stands out by pairing an FDA-cleared diagnostic platform with a suite of algorithms specifically designed for drug development endpoints—AIM-MASH is the first FDA-qualified AI for MASH clinical trials, which is a significant differentiator for biopharma partners. The platform's AISight® brings case management and image management under one roof, reducing workflow friction. The backing of 450+ pathologists and 32.5M+ annotations suggests a strong data moat. However, the tool is not for everyone. Small labs without digitized slide infrastructure will find little value, and enterprise pricing is opaque and likely prohibitive. The lack of public integration documentation could slow down adoption in IT environments. Additionally, the recent HN activity on A* pathfinding is unrelated and doesn't indicate any product changes. Where it fits: large central labs, biopharma R&D, and academic medical centers that already run digital pathology. Where it doesn't: solo pathologists or small clinics seeking a low-cost, plug-and-play solution.
Researching PathAI? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas PathAI actually fits — and what changes day-one when you adopt it.
You need to quantify PD-L1 expression across hundreds of slides for a clinical trial endpoint.
Outcome: PathAI's AIM-PDL1 automatically scores slides, reducing manual pathologist time and ensuring consistency, accelerating your endpoint analysis.
Your lab handles primary diagnosis for multiple sites and wants to reduce turnaround.
Outcome: With AISight and FDA-cleared algorithms, you can triage cases and get AI-assisted reads, cutting reporting time while maintaining accuracy.
You're running a MASH clinical trial and need FDA-qualified AI to assess histological endpoints.
Outcome: AIM-MASH provides a standardized, FDA-qualified readout, improving trial reliability and speeding up publication timelines.
Use Cases
- Pathologists reviewing cancer biopsies with AI assistance to reduce diagnostic time
- Biopharma companies analyzing tissue samples for clinical trial endpoints
- Labs quantifying biomarkers for personalized treatment decisions
- Hospitals aiming to reduce turnaround times for pathology reports
- Research institutions conducting high-volume biomarker studies
Limitations
Enterprise pricing requires a custom quote and may be prohibitive for small labs; the platform requires digitized slides to deliver value; it is not available for direct purchase online; integration details are not publicly documented; deployments are vendor-dependent with dedicated support.
as of 2026-08-30
Verification history
We have re-verified PathAI 20 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-checked, vendor evidence unchanged
- — re-checked, vendor evidence unchanged
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Showing the 6 most recent of 20 verification passes.
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where PathAI's pricing actually pencils out — and where peers do it cheaper.
PathAI's contact-based pricing fits large pharma and central labs that can negotiate volume-based deals. It's likely costlier than alternatives like Paige or Lunit, which offer more transparent tiers, but the investment is justified by FDA-qualified algorithms and deep biopharma integration.
Setup time & first value
How long it actually takes to get something useful out of PathAI — broken out by persona, not the marketing-page minute.
For large labs with existing scanner infrastructure, expect a few weeks for platform onboarding and validation. For biopharma partners, initial deployment can take 1-3 months given custom integrations and assay validation.
Resources & Guides
Tutorials & Learning
Official links
Frequently Asked Questions
Used PathAI? Help shape our editorial sentiment research.